{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-010541","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.626341+00:00","generated_at":"2026-05-21T05:26:47.430168+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lantern Pharma Q1 net loss $4.5M; LP-184 Phase 1a enrollment to complete by June 2025","bullets":["Cash and equivalents $19.7M as of Mar 31, 2025, down from $24.0M at Dec 31, 2024.","Net loss $4.5M ($0.42/share) vs $5.4M ($0.51/share) in Q1 2024; R&D expense $3.3M vs $4.3M.","LP-184 Phase 1a solid tumor trial enrollment expected to finish by end of June 2025; full data readout in Q3 2025.","FDA cleared Phase 1b/2 protocols for LP-184 in TNBC (with olaparib) and STK11/KEAP1-mutant NSCLC.","LP-300 HARMONIC trial additional data including Asian expansion cohort anticipated in Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-010541","json":"https://secwatch.observer/filing/0001641172-25-010541.json","markdown":"https://secwatch.observer/filing/0001641172-25-010541.md","text":"https://secwatch.observer/filing/0001641172-25-010541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000164117225010541/0001641172-25-010541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000164117225010541/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:26:47.430168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}